CARBIZOLE Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

SQUARE PHARMACEUTICALS LTD, Bangladesh

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    Carbimazole 5mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    Indication:

    Carbimazole is indicated in the management of hyperthyroidism, thyrotoxicosis (including thyroid storm), and also for the preparation of patients for thyroidectomy. Carbimazole can also be used in combination with radio­active ablative therapy.

    Dosage and adminstration:

    Adults: the initial dose: 20-60mg, in 2-3 divided doses until the patient is euthyroid. Daily dosage should be divided.

    Maintenance regimen: dose is gradually reduced to maintain a euthyroid state. Final dosage is usually in the range of 5-15mg/day which may be taken as a single daily dose.

    Neonates & Children below 12 years:

    The usual initial dose is 250mcg/Kg/day in divided doses

    Duration of treatment:

    18 to 24 months

  • ហាមប្រើ

    Hypersensitivity to carbimazole or other thiourea antithyroid agents.

  • ផលរំខាន

    Side-effects may include rash, pruritis, skin pigmentation, paraesthesias, urticaria, headache, arthralgia, and gastro­intestinal disturbances (including nausea, vomiting and gastric discomfort), and abnormal hair loss. Drug fever, a lupus-like syndrome, vasculitis and nephritis, and hepatic disorders, most commonly jaundice, and taste disturbances following carbimazole therapy have been reported.

  • អន្តរប្រតិកម្ម

    Carbimazole may interact adversely with other medicines. Iodine or iodine excess may decrease the response to Carbimazole, requiring an increase in dosage or longer duration of therapy with antithyroid agents.

    As thyroid and metabolic status of patient decreases toward normal, response to oral anticoagulants may decrease, however, if thioamide-induced hypoprothrombinemia occurs, anticoagulant effects may be enhanced. Adjustment of oral anticoagulant dosage on the basis of prothrombin time is recommended. Serum concentrations of digoxin and digitoxin have been reported to increase as the thyroid and metabolic status of patients taking antithyroid agents decreased, reduction in dosage of any digitalis glycoside may be necessary as patients become euthyroid.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    Carbimazole may be given during pregnancy to a thyrotoxic patient, but the smallest effective dose should be used a overdosage adversely affects the foetus. Carbimazole crosses the placenta and is excreted into the breast milk: Carbimazole may, therefore, cause foetal or neonatal hypothyroidism and goitre.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    Carbimazole should be given with the utmost caution, or not at all, if there is any degree of tracheal obstruction, as high dosages may produce thyroid enlargement and obstructive symptoms may become marked.

  • សកម្មភាពឱសថ

    Carbimazole is an anti-thyroid substance which depresses the formation of thyroid hormone. It reduces the uptake and concentration of inorganic iodine by the thyroid but its main effect is to reduce the formation of di-iodotyrosine and thyroxine. Carbimazole is absorbed rapidly from the gastro­intestinal tract and is widely distributed throughout the body. Carbimazole is completely metabolised to methimazole and it is the metabolite that is responsible for its clinical activity. Carbimazole readily crosses the placental barrier and also attains a high concentration in the milk of lactating patients.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp